$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H1 2017
[Report Updated: 31-03-2017]

Published by Global Markets Direct: 31 Mar 2017 | 51261 | In Stock
Related Topics: Healthcare , Infectious Disease

Introduction

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Marburgvirus Infections – Pipeline Review, H1 2017, provides an overview of the Marburgvirus Infections (Infectious Disease) pipeline landscape.

Marburg hemorrhagic fever is a rare, acute infectious which affects both human and nonhuman primates. Symptoms include fever, headache, chills, weakness, diarrhea, stomach pain and weight loss.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Marburgvirus Infections – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Marburgvirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Marburgvirus Infections (Marburg Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 11 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively.

Marburgvirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Marburgvirus Infections (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Marburgvirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Marburgvirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Marburgvirus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Marburgvirus Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Marburgvirus Infections (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Marburgvirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H1 2017 [Report Updated: 31-03-2017]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Marburgvirus Infections (Marburg Hemorrhagic Fever) – Overview

    Marburgvirus Infections (Marburg Hemorrhagic Fever) – Therapeutics Development

    Pipeline Overview

    Pipeline by Companies

    Pipeline by Universities/Institutes

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Marburgvirus Infections (Marburg Hemorrhagic Fever) – Therapeutics Assessment

    Assessment by Target

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Marburgvirus Infections (Marburg Hemorrhagic Fever) – Companies Involved in Therapeutics Development

    Arno Therapeutics Inc

    BioCryst Pharmaceuticals Inc

    Emergent BioSolutions Inc

    Fab'entech SA

    GeoVax Labs Inc

    Integrated BioTherapeutics Inc

    Johnson & Johnson

    Microbiotix Inc

    NanoViricides Inc

    Profectus BioSciences Inc

    Rodos BioTarget GmbH

    Sarepta Therapeutics Inc

    Vaxart Inc

    Marburgvirus Infections (Marburg Hemorrhagic Fever) – Drug Profiles

    (Ebola + Marburg) (monovalent) vaccine – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    (Ebola + Marburg) (trivalent) vaccine – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    (Ebola + Marburg) vaccine – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    (Ebola [Sudan, Zaire] + Marburg) vaccine – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    (Ebola [Sudan] + Marburg) vaccine – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    1-E703 – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Antibodies for Ebola and Marburg Viral Infections – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    AR-12 – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    ARD-5 – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    AVI-7288 – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    FDX-000 – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    galidesivir – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    GOVXE-301 – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    GOVXE-302 – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Marburg vaccine – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Monoclonal Antibodies for Ebola and Marburg Infections – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Monoclonal Antibody for Marburg Virus – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    MR-78 – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    NP-026 – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    RBT-05 – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules for Ebola and Marburg Infections – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules for Ebola and Marburg Infections – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules for Ebola and Marburg Virus Infections – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit VP40 for Ebola and Marburg Viral Infections – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Marburgvirus Infections (Marburg Hemorrhagic Fever) – Dormant Projects

    Marburgvirus Infections (Marburg Hemorrhagic Fever) – Discontinued Products

    Marburgvirus Infections (Marburg Hemorrhagic Fever) – Product Development Milestones

    Featured News & Press Releases

    Jan 19, 2016: Profectus BioSciences Initiates Ebola Vaccine Phase 1 Clinical Trial

    Nov 17, 2015: Profectus Presents Preclinical Data Demonstrating that a Single Dose of Multi-Component Vaccine Provides Complete Protection Against Zaire and Sudan Species of Ebola Virus and Marburg Virus

    Sep 08, 2015: GeoVax Ebola Vaccine Proven Effective in Rodent Models

    Jul 22, 2015: Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus platform

    May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research

    Apr 08, 2015: Profectus BioSciences Ebola Vaccine Shown Effective and Safe in Providing Rapid, Single-Dose Protection Against Current "Makona" Ebola Outbreak Strain in Non-Human Primates

    Mar 31, 2015: BioCryst Awarded BCX4430 Advanced Development Contract

    Mar 25, 2015: IBT Presents Pan-Ebola and Pan-Filovirus Monoclonal Antibodies

    Jan 22, 2015: NanoViricides Reports That It Has Shipped anti-Ebola Drug Candidates For Testing to a BSL-4 Hi-Security Biocontainment Laboratory

    Dec 23, 2014: BioCryst Announces Study Results for BCX4430 in a Non-Human Primate Model of Ebola Virus Infection

    Oct 31, 2014: Profectus BioSciences Receives .5 Million Department of Defense Funding to Manufacture Trivalent VesiculoVax-Vectored Vaccine to Protect Against all Ebola and Marburg Viruses

    Oct 27, 2014: NanoViricides Signs CRADA for Material Transfer with USAMRIID for Evaluating Its Anti-Ebola Drug Candidates

    Sep 18, 2014: BioCryst Receives Additional NIAID Funding for Manufacture and Development of BCX4430 to Treat Hemorrhagic Virus Diseases

    Jul 31, 2014: UTMB researchers receive over million to develop treatment for deadly Ebola and Marburg viruses

    Feb 10, 2014: Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

51261 | GMDHC9124IDB

Number of Pages

84

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2018
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2018SummaryGlobal Markets ...
26 Sep 2018 by Global Markets Direct USD $2,000 More Info
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H1 2018
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H1 2018SummaryGlobal Markets ...
13 Mar 2018 by Global Markets Direct USD $2,000 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H1 2017 [Report Updated: 31-03-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...